Article
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Nov 2013
Chan Kee, Lai Mai Ngan, Groessl Erik J, Hanchate Amresh D, Wong John B, Clark Jack A, Asch Steven M, Gifford Allen L, Ho Samuel B
Abstract excerpt
BACKGROUND & AIMS: The Veterans Health Administration (VHA) is the largest single provider of care for hepatitis C virus (HCV) infection in the United States. We analyzed the cost effectiveness of treatment with the HCV protease inhibitors boceprevir and telaprevir in a defined managed care population of 102,851 patients with untreated chronic genotype 1 infection. METHODS: We used a decision-analytic Markov...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.